SCN5A and myotonic dystrophy type 1: In principle, CRISPR strategy could normalize the splicing of key cardiac ion channels (e.g., SCN5A, CANA1C, KCND3) and gap junction proteins, which eventually reduce conduction abnormalities and arrhythmogenesis in DM1 patients.